Nine new procedure and one diagnosis codes added to private reimbursement schedule in England

Apr 2019

The Clinical Coding and Schedule Development (CCSD) group develop and maintains procedural and diagnostics nomenclature for private payers in England. New diagnostic codes concern circulating tumor DNA profile for the different type of cancers, myriad Prolaris test, PET Scan with florbetapir, etc. and a procedure code for robotic-assisted radical hysterectomy and lymphadenectomy. The codes are introduced with a recommended adoption date being the 1st of May 2019. The documents also contain a list of textual changes in codes and an updated list of unacceptable combinations of codes.

The CCSD Group has approved the following diagnostic codes for publication to the CCSD Schedule in February 2019 with a recommended adoption date being the 1st of May 2019:

Circulating tumor DNA profile for breast cancer (Guardant 360) (3100G)
Circulating tumor DNA profile for upper gastrointestinal cancer (Guardant 360) (3101G)
Circulating tumor DNA profile for colorectal cancer (Guardant 360) (3102G)
Circulating tumor DNA profile for cancer of unknown primary (Guardant 360) (3103G)
Myriad Prolaris (3015G)
PET Scan with florbetapir (IM371)
Gene Panel Myriad Colaris Plus with the colorectal high-risk panel (3016G)
B Cell Clonality (3017G)
ALCA – Anti-Liver Cytosol (LC1) Antibodies (0101B)

See full details here.

The new procedure code “Robotic-assisted radical hysterectomy and lymphadenectomy (Wertheim's) +/- ureterolysis” (Q0711) was also recommended for adoption. See full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

NHS Insights Prioritisation Programme in England

Mar 2022

The NHS Insights Prioritisation Programme (NIPP) is commissioned by the NHS Accelerated Access Collaborative (AAC) and the National Institute for Health Research (NIHR). It is designed to accelerate the evaluation and implementation of innovation that supports post-pandemic ways of working, builds service resilience, and delivers benefits to patients. Fourteen projects have been funded and have now commenced activity that will be ongoing until March 2023.

2022 RIHN and Supplementary list for IVD tests published in France

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Draft Order amending the Common Package of Benefits of the Spanish National Health System

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

New procedure and diagnostic codes added to the private reimbursement schedule in England

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Theme survey on products for monitoring and diagnostics of sepsis launched by Swedish TLV

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.